ORIGINAL RESEARCH
Published on 14 Oct 2025
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China
doi 10.3389/fpubh.2025.1652917
- 1,031 views
